title: Value of combined technetium-99m hydroxy methylene diphosphonate and thallium-201 imaging in detecting bone metastases from thyroid carcinoma.
abstract: Detectability of bone metastases from differentiated thyroid carcinoma by technetium-99m hydroxymethylene diphosphonate ([99m]Tc-HMDP) bone scan is considered to be poor. Thallium-201 (201Tl) is also widely used for detecting metastatic lesions. Our present study was aimed at the evaluation of the combined use of (99m)Tc-HMDP and 201Tl imaging in successful detection of bone metastases from differentiated thyroid carcinoma. Twenty-seven thyroidectomized thyroid cancer patients (19 females, 8 males; 12 papillary type, 15 follicular type) with 77 bone lesions were included in this retrospective study. All of these patients received ablative doses of radioiodine. Thyroidal origin of the lesions was proved by positive iodine-131 (131I) uptake. In 131I-negative lesions, histological proof or absence of tumor markers other than thyroglobulin was considered when computed tomography (CT) and/or magnetic resonance imaging (MRI) suggested metastatic nature of the lesions. Of the 77 lesions, 58 (75.3%) were positive and 19 were negative in the (99m)Tc-HMDP bone scintigraphy, whereas 53 lesions (68.9%) could be detected by 201Tl scintigraphy. However, within the 19 (99m)Tc-HMDP-negative lesions, 14 showed abnormal accumulation of 201Tl, and within the 24 201Tl negative lesions, 19 were positive in (99m)Tc-HMDP scan. This resulted in a combined sensitivity of 93.5%. Our present study concludes that combined (99m)Tc-HMDP and 201Tl imaging is a sensitive and effective method for detecting bone metastases from thyroid carcinoma.
authors.affiliation: Department of Nuclear Medicine, Kyoto University School of Medicine, Japan.
authors.forename: M S
authors.initials: MS
authors.lastname: Alam
authors.forename: R
authors.initials: R
authors.lastname: Takeuchi
authors.forename: K
authors.initials: K
authors.lastname: Kasagi
authors.forename: T
authors.initials: T
authors.lastname: Misaki
authors.forename: S
authors.initials: S
authors.lastname: Miyamoto
authors.forename: Y
authors.initials: Y
authors.lastname: Iida
authors.forename: A
authors.initials: A
authors.lastname: Hidaka
authors.forename: J
authors.initials: J
authors.lastname: Konishi
mesh_terms: D018263:Adenocarcinoma, Follicular / Q000000981:diagnostic imaging* / Q000556:secondary; D000328:Adult; D000368:Aged; D001859:Bone Neoplasms / Q000000981:diagnostic imaging* / Q000556:secondary; D002291:Carcinoma, Papillary / Q000000981:diagnostic imaging* / Q000556:secondary; D005260:Female; D006801:Humans; D007457:Iodine Radioisotopes / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D011877:Radionuclide Imaging; D019275:Radiopharmaceuticals; D012189:Retrospective Studies; D012680:Sensitivity and Specificity; D013669:Technetium Tc 99m Medronate / Q000031:analogs & derivatives*; D013794:Thallium Radioisotopes; D013964:Thyroid Neoplasms / Q000473:pathology* / Q000532:radiotherapy
chemical_list: D007457:Iodine Radioisotopes; D019275:Radiopharmaceuticals; D013794:Thallium Radioisotopes; C024226:technetium Tc 99m hydroxymethylene diphosphonate; D013669:Technetium Tc 99m Medronate